AngioDynamics, Inc. (ANGO)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$15.20-1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ANGO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -78.0% |
| Our one-year growth estimate | diamond | 6.1% |
Growth built into the price is above our model estimate.
The price assumes 84.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 26 industry peers
ANGO — litigation filed
Dated 2026-04-23
Other Events On April 23, 2026, AngioDynamics, Inc. (the “Company” or “AngioDynamics”) filed a complaint commencing a patent infringement lawsuit in the United States District Court for the District of Delaware against Endovascular Engineering, Inc. (“E2”). The complaint alleges that E2’s Hēlo Thrombectomy System unlawfully incorporates several features protected by registered patents held by the Company, including relating to the Company’s proprietary self-expanding funnel technology and rel…
Why it matters: New partnerships could enhance market position and drive growth in key segments.
Supportive ifA new partnership was announced. It helps improve market access.
Worry ifNo new partnerships announced in the next quarter.
Why it matters: New partnerships could enhance market position and drive future growth.
Supportive ifNew strategic partnerships were announced in Q3.
Worry ifNo new strategic partnerships announced in Q3.
Why it matters: Meeting the sales target shows growth and good strategy execution.
Supportive ifNet sales for FY 2026 reach between $313.5M and $315.5M.
Worry ifNet sales for FY 2026 fall below $313.5M, indicating weaker performance.
Why it matters: This approval would help the AlphaReturn Blood Management System grow. It will improve its market position.
Supportive ifFDA IDE approval is granted for the APEX-Return study.
Worry ifFDA does not grant IDE approval for the APEX-Return study.
Why it matters: The lawsuit result could change AngioDynamics' market position. It may also lower investor trust.
Worry ifA favorable ruling or settlement in the lawsuit.
Less concerning ifA decision against AngioDynamics could hurt them. A long legal battle without a solution is also a risk.
Why it matters: Keeping gross margin is important for making money. It affects overall financial results.
Supportive ifGross margin for Q4 FY 2026 stays between 53.5% and 55.5%.
Worry ifGross margin for Q4 FY 2026 falls below 53.5%, indicating margin pressure.
Why it matters: The earnings report will show if AngioDynamics can improve its loss-making status. Investors will focus on revenue and profit trends.
Watch forEarnings report shows revenue growth above 10% year over year.
Also watch forEarnings report shows revenue decline or continued losses.
Why it matters: If the health care sector's revenue growth speeds up, it could benefit AngioDynamics. A stronger sector may improve investor sentiment.
Supportive ifSector revenue growth is speeding up again. It is now above 10% year over year.
Worry ifSector revenue growth is slowing down. It is now below 10% year over year.
Why it matters: Strong growth in Med Tech sales shows the company's ability to capture market share. This supports the ongoing transformation strategy.
Supportive ifMed Tech net sales growth exceeds 15% year over year in Q3.
Worry ifMed Tech net sales growth falls below 15% year over year in Q3.
Why it matters: Approval for the RELIEF study could expand the NanoKnife market. This would support long-term growth potential.
Supportive ifThe FDA approved the RELIEF study. It will test NanoKnife IRE for benign prostatic hyperplasia.
Worry ifFDA does not grant approval for the RELIEF study.
Why it matters: Keeping a strong gross margin is important for making money. It shows how well the company controls costs.
Supportive ifGross margin remains above 53.5% in Q3.
Worry ifGross margin drops below 53.5% in Q3.
Why it matters: Achieving positive cash flow is key for financial health. It shows the company can fund operations without external help.
Supportive ifCompany reports positive free cash flow for Q4.
Worry ifCompany reports negative free cash flow for Q4.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $333 loss on $10,000 · 3.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,889 loss on $10,000 · 28.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.